News

If there’s one thing to know about Nigel, it’s that he loves typography. Today was an excellent opportunity for him to nerd out about it while discussing the origins of our logo. Check out the full journey on www.pharmasalmanac.com.

A fascinating presentation from Dr. Hollanbaugh, highlighting the discussion around Interleukin-2 (IL-2) inhibitors, which have emerged as a pivotal class of therapeutic agents, particularly in the realm of immunology and oncology.

Day Two of TAS25 kicks off with a presentation by Professor Madelon Maurice from the Madelon Maurice Lab in Holland.

Nigel is back in Porto for the first time in 54 years thanks to the team at FairJourney Biologics.

For a while, it was just the two lads working out of Nigel’s apartment. As the pipeline grew, so did the staff, and they needed to begin scaling the whole operation. Things were starting to get real. Check out the full journey on www.pharmasalmanac.com.

Exploring the agency’s deep-rooted exhibit culture, which dates all the way back to work with UNICEF and UNFPA in the early ’90s, on today’s Road to 30 Years installation. Check out the full journey on www.pharmasalmanac.com.

Peter Senter, Ph.D., Janine Schuurman, Ph.D., and Greg Thurber, Ph.D. — now that’s a lineup.

Peter Senter, Ph.D., is the keynote for TAS25. Peter joined Seattle Genetics in 1998 and was part of the research team focused on anticancer therapies before the company’s $43 billion sale to Pfizer in 2023.

So grateful to the team at FairJourney Biologics for inviting our team to TAS25, their high-science discovery show in Porto, Portugal.

That’s Nice is visiting the FairJourney Biologics facilities in Porto, Portugal, as a kick-off to TAS2025: The Anti-Body Series.